Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Ebastine is a second-generation antihistamine which undergoes transformation to its active metabolite, carebastine. Its antihistaminic and antiallergic effects have been demonstrated in in vitro and in vivo studies, in addition to data obtained from clinical trials.
Patients with allergic rhinitis or chronic idiopathic urticaria experienced significant improvement in their symptoms with ebastine 10 or 20mg once daily. Some studies in patients with seasonal allergic rhinitis (SAR) have indicated trends towards greater efficacy with the 20mg than the 10mg dose, although only 1 study has shown statistically significant benefits. In comparative trials in patients with SAR, ebastine 10mg was as effective as most other second-generation antihistamines, including astemizole, azelastine, cetirizine, loratadine and terfenadine. Ebastine 20 mg/day was significantly superior to loratadine 10 mg/day in patients with SAR according to effects on secondary efficacy variables in comparative studies; 1 study found significantly greater changes from baseline in mean total symptom score with ebastine 20mg (−43 vs −36% with loratadine, p = 0.045). In patients with perennial allergic rhinitis, ebastine 10 or 20mg daily was significantly more effective than loratadine in reducing total symptom scores from baseline in 1 comparative study.
There have been no reports of serious adverse cardiac effects during ebastine therapy. Increases in corrected QT interval have been observed during clinical trials; however, these have not been considered clinically significant and were generally of similar magnitude to those seen with loratadine.The normal diurnal variation in QTc interval and the problems associated in correcting for changes in heart rate also complicate assessment of this issue. The incidence of adverse events during ebastine treatment is not significantly greater than that observed with placebo or other second-generation antihistamines.
Conclusions: Ebastine 10mg daily is a well tolerated and effective treatment for allergic rhinitis and chronic idiopathic urticaria. At this dosage, it is as effective as the other second-generation antihistamines against which it has been compared. Ebastine 20mg has similar tolerability to the 10mg dose, and trends towards greater efficacy with the higher dose have been shown in some studies. Ebastine does not appear to be associated with any significant cardiac adverse events. Ebastine is a useful treatment option for patients with allergic rhinitis or chronic idiopathic urticaria.
Single doses of ebastine (10mg or more) are significantly better than placebo in inhibiting histamine-induced wheal and flare. After a week of treatment, 1 study found that ebastine 10 mg/day was as active in inhibiting wheal and flare response as terfenadine 60mg twice daily and loratadine 10 mg/day. A number of trials found cetirizine 10 mg/day superior in activity to ebastine 10 mg/day at assessments performed 2 to 3 hours after drug administration; however, these differences were not detected at 24 hours. In addition, ebastine 20 mg/day was superior in activity to loratadine 10 mg/day; ebastine 20 mg/day was also more active than fexofenadine 120 mg/day at tests performed 24 hours after drug administration, although both agents were similar in effect at 4 hours.
There were no significant differences between placebo and ebastine recipients in wheal or flare responses to histamine challenge 5 days after stopping treatment (7 days of either placebo or ebastine 20 mg/day).
The antiallergic effects of ebastine have been demonstrated in in vitro and in vivo studies; assessment has included nasal challenge tests, skinprick testing, and measurement of the levels of allergic mediators in adults and children with allergies.
Single and multiple therapeutic doses of ebastine did not impair psychomotor performance or driving ability in volunteers. In addition, treatment with ebastine 20mg daily for 1 week did not potentiate the depressant effects of ethanol or the psychomotor performance impairing effects of diazepam.
Concerns regarding possible adverse cardiac effects of second-generation antihistamines have been complicated by contradicting results from in vivo and in vitro models. In clinical studies, difficulties have arisen because of diurnal variation in the QT interval and the use of differing heart rate correction formulae that may provide misleading results. However, most studies in animal in vivo or in vitro models have found that any changes in QTc interval associated with ebastine are noticeably less than those seen with similar concentrations of terfenadine and are not considered to be clinically significant. No clinically relevant abnormalities were found on 24-hour Holter monitoring of healthy elderly and young volunteers who received 10 days of treatment with ebastine 10 mg/day or placebo. Data obtained from >1000 patients enrolled in controlled trials also indicate that ebastine 10 or 20 mg/day is not associated with clinically significant changes in corrected QT (QTc) interval.
Although increased plasma levels of ebastine have been observed during coadministration with ketoconazole or erythromycin, any associated changes in QTc interval have been small and not clinically significant.
Plasma levels of ebastine are low or undetectable after oral administration; therefore, pharmacokinetic studies generally measure the concentrations of the active metabolite, carebastine. In vitro studies using human liver microsomes indicate that, although the metabolism of ebastine does involve the cytochrome P450 (CYP) CYP3A4 enzyme, the conversion of ebastine to carebastine appears to be mediated by other unidentified enzymes. The pharmacokinetics of carebastine are linear.
After oral administration of ebastine 10mg to healthy volunteers, peak plasma concentrations (Cmax) of carebastine ranged from 0.09 to 0.12 mg/L, with a time to reach Cmax of 2.6 to 5.7 hours. Values for the area under the plasma concentration-time curve (AUC) ranged from 1.75 to 2.94 mg/L·h. Results from 2 studies found the volume of distribution of carebastine to be 89.5 and 123L. The elimination half-life (t1/2β) of carebastine ranged from 10.3 to 19.3 hours, with the main route of excretion being the kidneys.
Pharmacokinetic parameters in children and elderly volunteers were generally similar to those seen in healthy adults, although values for Cmax and AUC were higher in children than in adults. Patients with hepatic or severe renal impairment (creatinine clearance <1.8 L/h/1.73m2) had significantly increased values for t1/2β compared with those obtained from healthy volunteers.
The metabolism of single doses of ebastine 20mg was significantly impaired in healthy volunteers receiving multiple doses of either ketoconazole or erythromycin (drugs that inhibit CYP metabolism). In contrast, cimetidine had no significant effects on the metabolism of a single dose of ebastine 20mg.
In clinical trials, ebastine 10 to 20mg once daily for 1 to 12 weeks was effective in the treatment of adults with allergic rhinitis. Although there is a lack of statistical data, studies in patients with seasonal allergic rhinitis (SAR) indicate a trend towards greater efficacy with ebastine 20mg than with 10mg, with 1 study showing significantly greater reductions in total symptom score with the higher dose (13.7 vs 11.8 with 10 mg, p = 0.027) in the subgroup of patients with more severe symptoms (defined as those with a baseline total symptom score greater than the mean for the study population).
In patients with SAR, comparative trials have shown ebastine 10 mg/day to be as effective at relieving symptoms as total daily doses of astemizole 10mg, azelastine 0.56mg (as an intranasal spray), cetirizine 10mg, loratadine 10mg and terfenadine 120mg. In 1 of 3 similarly designed trials (all unpublished, double-blind and placebo-controlled), ebastine 20 mg/day produced significantly greater percentage reductions from baseline in mean total symptom score than those seen with loratadine 10 mg/day (−43 vs −36%, p = 0.045). Although changes in mean total symptom score did not differ significantly between treatments in other studies, all found ebastine 20mg to be significantly superior to loratadine according to some or most of the secondary efficacy variables. Ebastine 20mg daily was also significantly superior to cetirizine 10mg daily in some of the variables assessed after 1 week in a double-blind study in 343 patients with SAR; however, at the end of the 2-week study, cetirizine had reached a similar level of efficacy.
Once-daily doses of ebastine 10mg and astemizole 10mg were similarly effective when used as prophylaxis against the onset of SAR symptoms in a non-blind randomised study in 217 patients with a history of SAR.
Data on efficacy of ebastine in children are limited; however, 1 double-blind study in 173 children with SAR found that ebastine 5 mg/day for 3 weeks significantly improved overall symptom scores compared with placebo.
Ebastine 10 and 20 mg/day are significantly more effective than placebo for improving symptoms of perennial allergic rhinitis (PAR). No significant differences have been found between the 2 doses. In 1 large comparative randomised double-blind trial in patients with PAR, ebastine 10 and 20mg were significantly more effective than loratadine 10mg at reducing total symptom scores from baseline. Ebastine 10mg daily was also as effective as cetirizine 10 mg/day in improving total PAR symptom scores from baseline during a 4-week trial; however, improvement was significantly faster with cetirizine, and significantly more cetirizine recipients were symptom-free by the end of the trial (17.8 vs 6.9% with ebastine, p = 0.02).
Ebastine 5 to 20mg daily is as effective in the treatment of chronic idiopathic urticaria as terfenadine 60mg twice daily, ketotifen 2mg once daily and astemizole 10mg once daily. Preliminary findings from studies also indicate benefits in the treatment of pruritic dermatoses, and significant improvements in morning peak expiratory flow rates in 20 patients with asthma were seen during treatment with ebastine.
Ebastine was well tolerated in clinical trials, with a similar incidence of adverse events to that observed with placebo. In comparative trials with other second-generation antihistamines, ebastine was at least as well tolerated as astemizole, cetirizine, loratadine and azelastine. There have been no significant differences in tolerability reported between ebastine 10 and 20mg.
The adverse events most commonly reported during treatment with ebastine 10 or 20mg were headache (≈6 to 13% of patients in individual trials), somnolence (1.4 to 9%) and dry mouth (4 to 7%). Less frequently occurring adverse events (<5% of patients) included asthenia, nausea, abdominal pain, gastrointestinal upset, altered appetite and insomnia.
Although both terfenadine and astemizole have been associated with serious cardiac abnormalities — in particular, ventricular arrhythmias — no such events have been reported during treatment with ebastine. Some studies have found small statistically significant increases in QTc interval (compared with baseline or placebo values) during treatment with ebastine 20mg daily; however, these differences were not considered clinically significant and were not sustained throughout the studies. Normal diurnal variation and the use of heart rate correction formulae also complicate the assessment of the significance of these changes. Comparative studies found similar percentages of patients with QTc intervals >0.444 seconds with ebastine (10 or 20mg) and loratadine 10mg. Analysis of pooled ECG data from a number of large clinical trials did not find any patients treated with ebastine who had QTc intervals of >0.5 seconds.
Laboratory tests failed to find any clinically significant differences between patients who received ebastine and those who received placebo or other second-generation antihistamines.
Dosage and Administration
Single daily oral doses of ebastine 10mg are effective in the treatment of adults with allergic rhinitis or chronic idiopathic urticaria; increasing the dose to 20mg daily does not significantly affect tolerability and may be of use in some patients. A dose of 5mg daily is recommended in children. Ebastine, like other antihistamines, should be used with caution in patients with known QTc prolongation.
- Lemanske, RF (1998) A review of the current guidelines for allergic rhinitis and asthma. J Allergy Clin Immunol 101: pp. S392-396
- Durham, S (1998) Summer hay fever. BMJ 316: pp. 843-5
- Levenson, T, Greenberger, PA (1997) Pathophysiology and therapy for allergic and nonallergic rhinitis: an updated review. Allergy Asthma Proc 18: pp. 213-20
- Fornadley, JA, Corey, JP, Osguthorpe, JD (1996) Allergic rhinitis: clinical practice guideline. Otolaryngol Head Neck Surg 115: pp. 115-22
- Bousquet, J (1998) Antihistamines in severe/chronic rhinitis. Clin Exp Allergy 28: pp. 49-53
- Allergy Eur J Allergy Clin Immunol Suppl 53: pp. 7-31
- Bachert, C (1998) Histamine — a major role in allergy?. Clin Exp Allergy 28: pp. 15-9
- Simons, FER (1994) Hi-Receptor antagonists: comparative tolerability and safety. Drug Saf 10: pp. 350-80
- Simons, FER, Simons, KJ (1999) Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet 36: pp. 329-52
- Wiseman, LR, Faulds, D (1996) Ebastine: a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Drugs 51: pp. 260-77
- Kukita, A, Kawashima, M, Harada, S (1994) Clinicopharmacological study of LAS-90: inhibitory effect on wheal and erythema induced by intradermal injection of histamine [in Japanese]. Rinsho Iyaku 10: pp. 103-11
- Buchmeier, A, Nelson, HS, Bucher, B (1994) Dose-response of prick skin test (PST) suppression by ebastine [abstract]. J Allergy Clin Immunol 93: pp. 163
- Simons, FER, Watson, WTA, Simons, KJ (1993) Pharmacokinetics and pharmacodynamics of ebastine in children. J Pediatr 122: pp. 641-6
- Gispert, J, Antonijoan, R, Barbanoj, M (1998) Pharmacodynamic assessment of the efficacy of single and multiple doses of ebastine, cetirizine and loratadine against histamine-induced cutaneous challenge in healthy volunteers [abstract]. J Allergy Clin Immunol 101: pp. S221
- Cassel, DA, Garcia, JD, Alderfer, VB (1995) Dose-response suppression of histamine-induced wheal and flare by ebastine in allergic rhinitis patients [abstract]. Allergy 50: pp. 105
- Westra S. Duration of inhibited skin reactivity to allergens and histamine following discontinuation of ebastine 20 mg. 5/4/99. Rhone Poulenc. [Data on file]
- Almeda, E, Daza, JC, Reyes, L (1992) A comparative study of ebastine and cetirizine effect on in-vivo test on children who are sensitive to olea pollen [abstract]. Allergy 47: pp. 99
- Almeda E, Daza JC, Reyes L, et al. A comparative study of ebastine and loratadine effect on in vivo test of children sensitive to olea pollen [abstract]. Allergy Clin Immunol News 1994 Suppl. 2:389
- Cuadra, J, Teruel, M, Teixido, P (1994) Assessment of the wheal size and skin blood flow of the erythema induced by histamine and its modification with cetirizine and ebastine: a crossover, double-blind study. Dermatology 188: pp. 131-4
- Rivest, J, Despontin, K, Ghys, L (1991) Pharmacological modulation by cetirizine and ebastine of the cutaneous reactivity to histamine. Dermatologica 183: pp. 208-11
- Torrent Farnells J, Segura J. Study of the antihistamine effect of LAS W090 (INN ebastine) in healthy volunteers. Single oral administration of LAS W-090 (10 mg) in human volunteers and a pharmacokinetic study of its acid metabolite. Rhône-Poulenc Rorer (Collegeville), 1984. Report no. Clin 1/5 and Bio 3/2 (Data on file)
- Carrenca FJ, Farnells JT, Pulido II, et al. Study of safety, pharmacokinetics and antihistamine effects of LAS W-090 at repeated doses in healthy volunteers. Rh one-Poulenc Rorer (Collegeville), 1986. Report No. Clin 1/7 (Data on file)
- Frossard, N, Melac, M, Benabdesselam, O (1998) Consistency of the efficacy of cetirizine and ebastine on skin reactivity. Ann Allergy Asthma Immunol 80: pp. 61-5
- Aparicio, S, Granel, C, Randazzo, L (1992) Studies of nonsedative antihistamines. II. Assessment of its antihistaminic potency. Allergol Immunopathol Madr 20: pp. 207-10
- Antonijoan, R, Gispert, J, Gich, I (1999) Double-blind, randomised, monocentre, placebo-controlled cross-over study to evaluate the inhibitory effects of single and repeated (5 days) oral doses of ebastine (20mg) and fexofenadine (120mg) against histamine-induced skin reactions in healthy volunteers. Almirall Prodesfarma, S.A. (Barcelona)
- Wood-Baker, R, Holgate, ST (1990) Dose-response relationship of the H1-histamine antagonist, ebastine, against histamine and methacholine-induced bronchoconstriction in patients with asthma. Agents Actions 30: pp. 284-6
- Roberts, DJ (1996) A preclinical overview of ebastine: studies on the pharmacological properties of a novel histamine H1 receptor antagonist. Drugs 52: pp. 8-14
- Yakuo, I, Inuj, A, Yabuuchi, M (1997) Effects of ebastine, a selective histamine H1 receptor antagonist, on experimental asthma in guinea pigs [abstract]. Jpn J Pharmacol 73: pp. 99P
- Fernández, L, Fernández del Cotero, JN, Rodríguez, F (1995) Protective effect of ebastine on the conjunctival provocation test with histamine [abstract no. P-0300]. Allergy 50: pp. 182
- Campbell, A, Michel, F-B, Bremard-Oury, C (1996) Overview of allergic mechanisms: ebastine has more than an antihistamine effect. Drugs 52: pp. 15-9
- Chanal, I, Maudino, G, Campbell, AM (1994) Efficacy of ebastine assessed by nasal challenge in a double-blind placebo-controlled study [abstract]. J Allergy Clin Immunol 93: pp. 272
- Horiguchi, T, Tachikawa, S, Kasahara, J (1999) Effect of ebastine on serum eosinophil cationic protein levels in patients with bronchial asthma. Clin Drug Invest 17: pp. 435-40
- Llupiá, J, Llenas, J, Palacios, JM (1997) In vitro and in vivo anti-leukotriene effects of ebastine [abstract]. Eur Respir J 10: pp. 439s
- Leroy T, Tasset C, Valentin B, et al. Comparison of the effects of cetirizine and ebastine on the skin response to histamine iontophoresis monitored with laser Doppler flowmetry. Dermatology 1998 (197): 146–51
- Monroe, EW, Daly, AF, Shalhoub, RF (1997) Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines. J Allergy Clin Immunol 99: pp. S798-806
- Bernstein, L, Storms, WW (1995) Summary statements of practice parameters for allergy diagnostic tests. Ann Allergy Asthma Immunol 75: pp. 543-52
- Roberts, DJ, Gispert, J (1999) The non-cardiac systemic side-effects of antihistamines: ebastine. Clin Exp Allergy 29: pp. 151-5
- Mattila, MJ, Kuitunen, T, Plétan, Y (1992) Lack of pharmacodynamic and pharmacokinetic interactions of the antihistamine ebastine with ethanol in healthy subjects. Eur J Clin Pharmacol 43: pp. 179-84
- Mattila, MJ, Aranko, K, Kuitunen, T (1993) Diazepam effects on the performance of healthy subjects are not enhanced by treatment with the antihistamine ebastine. Br J Clin Pharmacol 35: pp. 272-7
- Matsunaga, K, Sato, T, Shuto, H (1998) Inhibition of neuronal dopamine uptake by some antiallergic drugs. Eur J Pharmacol 350: pp. 165-9
- Simons, FER, Simons, KJ (1994) The pharmacology and use of H1-receptor-antagonist drugs. N Engl J Med 330: pp. 1663-70
- Llenas, J, Bou, J, Massingham, R (1992) Preclinical safety studies with ebastine. II. Pharmacological effects on the cardiovascular system. Drugs Today 28: pp. 29-34
- Gras, J, Llenas, J, Palacios, JM (1996) Ebastine is without effect in a sensitive experimental model for detecting prolongation of the QTC interval [abstract]. Allergy 51: pp. 188
- Mann Ko, C, Ducic, I, Fan, J (1997) Suppression of mammalian K+ channel family by ebastine. J Pharmacol Exp Ther 281: pp. 233-44
- Valenzuela, C, Delpón, E, Franqueza, L (1997) Comparative effects of nonsedating histamine H1 receptor antagonists, ebastine and terfenadine, on human Kv1.5 channels. Eur J Pharmacol 326: pp. 257-63
- Hey, JA, Prado, M, Sherwood, J (1996) Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects. Arzneimittel Forschung 46: pp. 153-8
- Heredia A, Beleta J, Llenas J, et al. Terfenadine and the main metabolite of loratadine release histamine from cardiac mast cells: possible cardiotoxic consequences [abstract]. Annual Meeting American College of Allergy, Asthma & Immunology 1996 Nov 8–13; 64
- Moss A. Panel discussion. Drug Saf 1999; 21 (Assessing the cardiac safety of ebastine) Suppl. 1: 81–7
- Lindquist, M, Edwards, IR (1997) Risks of non-sedating antihistamines. Lancet 349: pp. 1322
- Funck-Bretano, C, Jaillon, P (1993) Rate-corrected QT interval: techniques and limitations. Am J Cardiol 72: pp. 17B-22B
- Molnar, J, Weiss, J, Zhang, F (1996) Evaluation of five QT correction formulas using a software-assisted method of continuous QT measurement from 24-hour Holter recordings. Am J Cardiol 78: pp. 920-6
- Sagie, A, Larson, MG, Goldberg, RJ (1992) An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol 70: pp. 797-801
- Garson, A (1993) How to measure the QT interval — what is normal?. Am J Cardiol 72: pp. 14B-6B
- Morganroth, J, Brozovich, FV, McDonald, JT (1991) Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 67: pp. 774-6
- Huang, M-Y, Argenti, D, Wilson, J (1998) Pharmacokinetics and electrocardiographic effect of ebastine in young versus elderly healthy subjects. Am J Ther 5: pp. 153-8
- Moss, AJ, Morganroth, J (1999) Cardiac effects of ebastine and other antihistamines in humans. Drug Saf 21: pp. 69-80
- Bruno, R, Baille, P, Rhodes, G (1998) An evaluation of the pharmacokinetic/pharmacodynamic (PK/PD) relationships with ebastine at high exposures [abstract no. 593]. J Clin Pharmacol 38: pp. 874
- Gillen, M, Pentikis, H, Rhodes, G (1998) Pharmacokinetic (PK) and cardiac safety studies of ebastine (EBA) and loratidine (LOR) administered with ketoconazole (keto) [abstract no. 579]. J Clin Pharmacol 38: pp. 867
- Wilson J, Huang M-Y, Garcia J, et al. An open-label interaction study between a single dose of ebastine and multiple doses of ketoconazole on the cardiac function and pharmacokinetic profile in healthy adult male volunteers. Rhône-Poulenc Rorer (Collegeville), 1994. Report No. EBA 127 (Data on file)
- Gillen, M, Pentikis, H, Rhodes, G (1998) Pharmacokinetic (PK) and pharmacodynamic (PD) interaction of ebastine (EBA) and erythromycin (ERY) [abstract]. J Clin Pharmacol 38: pp. 878
- Wilson J, Huang M-Y, Garcia J, et al. An open-label interaction study betweem a single dose of ebastine and a mulitple dose of erythromycin stearate on the cardiac function and pharmacokinetic profile in healthy adult male volunteers. Rhône-Poulenc Rorer (Collegeville), 1994. Report no. EBA 130 (Data on file)
- Nagasawa K, Saito H, Nomura A, et al. Effect of ebastine with concomitant use of erythromycin on electrocardiographic findings and pharmacokinetics [abstract]. 6th International Congress on Cardiovascular Pharmacotherapy 1996 Feb 26–29: Sydney, Australia
- Yamaguchi, T, Hashizume, T, Matsuda, M (1994) Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects. Arzneimittel Forschung 44: pp. 59-64
- Vincent, J, Liminana, R, Meredith, PA (1988) The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects. Br J Clin Pharmacol 26: pp. 497-502
- Martínez-Tobed, A, Tarrús, E, Segura, J (1992) Pharmacokinetic studies of ebastine in rats, dogs and man. Drugs Today 28: pp. 57-67
- Nakamura, T, Mizorogi, Y, Matsuda, M (1994) Pharmacokinetics of ebastine in the elderly. Rinsho Iyaku 10: pp. 47-54
- Huang, M-Y, Wilson, J, Argenti, D (1993) Comparative pharmacokinetics of ebastine/carebastine in liver cirrhosis and healthy volunteers following administration of a 10 mg ebastine tablet. Pharm Res 10: pp. S-390
- Huang, M-Y, Argenti, D, Wilson, J (1993) Single dose and steady-state pharmacokinetics of carebastine following administration of 10 mg ebastine tablets once daily in healthy elderly and young adults. Pharm Res 10: pp. S-391
- Investigator’s Brochure. Rhône-Poulenc Rorer (Collegeville), 1995. (Data on file)
- Scheen, AJ, Roux, Y, Gaillard, C (1995) Effect of food intake on the excretion balance, metabolism and pharmacokinetics of ebastine in healthy volunteers [abstract]. Therapie 50: pp. 496
- Stamidis Pentikis, H, Huang, M-Y, Dorr, MB (1997) The effect of food on the bioavailability of ebastine. Am J Ther 4: pp. 80-4
- Fujii, T, Matsumoto, S, Amejima, H (1994) Absorption, distribution, metabolism and excretion of [14C] ebastine after a single administration in rats. Arzneimittel Forschung 44: pp. 527-38
- Hashizume, T, Mise, M, Terauchi, Y (1998) N-dealkylation and hydroxylation of ebastine by human liver cytochrome P450. Drug Metab Dispos 26: pp. 566-71
- Fujii, T, Matsumoto, S, Hatoyama, T (1997) Studies on the first-pass metabolism of ebastine in rats. Arzneimittel Forschung 47: pp. 949-53
- Van-Rooij, J, Schoemaker, HC, Bruno, R (1993) Cimetidine does not influence the metabolism of the Hi-receptor antagonist ebastine to its active metabolite carebastine. Br J Clin Pharmacol 35: pp. 661-3
- Ankier, SI, Warrington, SJ (1989) A double-blind placebo-controlled study of the efficacy and tolerability of ebastine against hay-fever in general practice patients. J Intern Med 226: pp. 453-8
- Molina, M, Cadahia, L, Cano, L (1989) Efficacy and tolerability of ebastine at two dose levels in the treatment of seasonal allergic rhinitis. Drug Invest 1: pp. 40-6
- Peláez, A (1996) Clinical efficacy of ebastine in the treatment and prevention of seasonal allergic rhinitis. Drugs 52: pp. 35-8
- Storms, WW (1996) Clinical studies of the efficacy and tolerability of ebastine 10 or 20mg once daily in the treatment of seasonal allergic rhinitis in the US. Drugs 52: pp. 20-5
- Banov CH, Chervinsky P, Munk ZM, et al. Multicenter double-blind parallel-group randomized comparisons of ebastine and placebo in patients with seasonal allergic rhinitis. Rhône-Poulenc Rorer (Collegeville), 1992. Report no. EBA 124 (Data on file)
- Grossman, J (1996) Multicentre double-blind placebocontrolled dose response study of ebastine in ragweed SAR patients [abstract]. Allergy 51: pp. 41
- Gehanno, P, Bremard-Oury, C, Zeisser, P (1996) Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults. Ann Allergy Asthma Immunol 76: pp. 507-12
- Bernstein, DI, Rio, M, Georges, GC (1999) Placebo controlled trial of ebastine 20 mg and 10 mg once daily versus loratidine 10 mg once daily in the treatment of seasonal allergic rhinitis (SAR) [abstract]. Eur J Allergy Clin Immunol 54: pp. 150
- Vervloet D, Valleteau A. A double-blind placebo-controlled study of the efficacy and safety of ebastine 20mg, ebastine 10mg, and loratidine 10mg in seasonal allergic rhinitis in Europe [poster]. European Academy of Allergology and Clinical Immunology; 1999 Jul 3–7; Brussels
- Ratner PH, Del Rio M, Georges GC, et al. Ebastine 20mg once daily is superior to loratidine 10mg once daily in relieving seasonal allergic rhinitis (SAR) symptoms [poster]. European Academy of Allergology and Clinical Immunology; 1999 Jul 3–7; Brussels
- Ankier SI, Jay L, Warrington SJ. Report on a placebo-controlled study in general practice to compare the efficacy and tolerability of ebastine and astemizole 10 mg against the symptoms of hay fever. Aventis. Report No. 61 (Pt IV.B. 1) [Data on file]
- Antépara, I, Jaúregui, I, Basomba, A (1998) Investigation of the efficacy and tolerability of azelastine nasal spray versus ebastine tablets in patients with seasonal allergic rhinitis [in Spanish]. Allergol Immunopathol Madr 26: pp. 9-16
- Conde Hernández, DJ, Palma Aqilar, JL, Delgado Romero, J (1996) Comparison of azelastine nasal spray and oral ebastine in treating seasonal allergic rhinitis. Curr Med Res Opin 13: pp. 299-304
- Antépara I, Basomba, Castillo, et al. Double-blind randomised parallel clinical trial to compare the efficacy and tolerability of ebastine 20 mg once daily with loratidine 10 mg once daily and placebo in the treatment of seasonal allergic rhinitis. Avenus. Report No. 72 (Pt IV.B.2) (Data on file)
- Ratner PH, Lim JC, Georges GC. Comparison of once-daily dosing of ebastine 20mg, ebastine 10mg, loratidine 10mg and placebo in the treatment of seasonal allergic rhinitis. Rhône-Poulenc Rorer Pharmaceuticals (Pennsylvania), 1999, July 12, 1999. (Data on file)
- Castro E, Molina E, Prieto L, et al. A comparative study of the efficacy and tolerability of ebastine (LAS W 0-90) and terfenadine in the treatment of seasonal allergic rhinitis. Aventis. Report No. 60 (Pt IV.B.1) [Data on file]
- Czarny D, Gillis D, Katelaris C, et al. A double-blind randomized controlled multicentre phase III efficacy and safety trial to assess the effect of ebastine (RP 64305) 10 mg (o.d) versus terfenadine 60 mg (b.i.d) and placebo given for a period of three weeks in the treatment of adult patients with seasonal allergic rhinitis. Aventis. Report No. 59 (Pt IV.B.1) [Data on file]
- Moreland TA, Pears JS, Mills MJ, et al. The effect of ebastine on warfarin kinetics and dynamics. 5th World Conference on Clinical Pharmacology & Therapeutics, 1992 Jul 26–31; Yokohama, Japan
- Luria, X, Robert, M, Antepara, I (1995) A double-blind placebo controlled study of the efficacy and tolerability of ebastine and loratidine in seasonal allergic rhinitis patients [abstract no. P-0350]. Allergy 50: pp. 199
- Ostrom, N, Welch, M, Morris, R (1994) Evaluation of ebastine (Eba), a new non-sedating antihistamine in children with seasonal allergic rhinitis (SAR) [abstract no. 261586]. J Allergy Clin Immunol 93: pp. 163
- Picado Vallés, C, Cadahia Garcia, A, Cisteró Bahima, A (1991) Ebastine in perennial allergic rhinitis. Ann Allergy 67: pp. 615-8
- Bousquet, J, Gaudaño, EM, Parma Carlos, AG (1999) A 12-week, placebo-controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis. Allergy 54: pp. 562-8
- Bronsky EA, Jacobson KW, Klimas JT, et al. Ebastine 20 mg once daily for oral treatment of patients with perennial alllergic rhinitis: a multicenter, double-blind, placebo-controlled study. Rhône-Poulenc Rorer, Collegeville, PA, 8129; May 1998. (Data on file)
- Baba, S, Ito, H, Takagi, I (1994) Early phase II study of LAS-90 on perennial allergic rhinitis [in Japanese]. Rinsho Iyaku 10: pp. 113-24
- Baba, S, Takagi, I, Saito, Y (1994) Clinical evaluation of LAS-90 on Japanese cedar pollinosis [in Japanese]. Rinsho Iyaku 10: pp. 147-61
- Baba, S, Takagi, I, Okuda, M (1994) Phase II study of LAS-90 on perennial allergic rhinitis: optimal dose finding study by double-blind technique [in Japanese]. Rinsho Iyaku 10: pp. 125-45
- Baba, S, Mamiya, S, Sakakura, Y (1994) Clinical trial of LAS-90 on perennial allergic rhinitis: a double blind study in comparison with ketotifen fumarate [in Japanese]. Rinsho Iyaku 10: pp. 1143-62
- Cadahia A, Picado C, Cisteró A, et al. Efficacy and tolerability of the H1-antihistamine ebastine in the treatment of perennial allergic rhinitis. Laboratorios Almirall, Barcelona. (Data on file)
- Davies, RJ (1998) Efficacy and tolerability comparison of ebastine 10 and 20mg with loratadine 10mg: a double-blind, randomised study in patients with perennial allergic rhinitis. Clin Drug Invest 16: pp. 413-20
- Murris-Espin, M, Melac, M, Charpentier, J-C (1998) Comparison of efficacy and safety of cetirizine and ebastine in patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol 80: pp. 399-403
- Bronsky, EA (1996) Efficacy and safety of ebastine 20mg once daily (AM) in the treatment of perennial allergic rhinitis (PAR) [abstract]. Allergy 51: pp. 42
- Aliaga Boniche, A, Olmos Acebes, L, Kisis, J (1999) Placebo controlled study of mizolastine 10 mg and ebastine 10 mg once daily in chronic idiopathic urticaria (CIU) [abstract no. P171]. Allergy 54: pp. 113-4
- Kukita, A, Harada, S, Yoshida, H (1994) Clinical study of LAS-90 on eczema/dermatitis, prurigo and pruritus cutaneus [in Japanese]. Rinsho Iyaku 10: pp. 73-88
- Davies, RJ (1997) Comparative efficacy and safety of once-daily ebastine 10 or 20mg and loratadine 10 mg in the treatment of perennial allergic rhinitis [abstract]. Allergy 52: pp. 168
- Cohen, B, Gehanno, P (1996) Comparison of the efficacy of ebastine 10mg and 20mg once daily with that of cetirizine 10mg once daily in adults with seasonal allergic rhinitis: a multicentre double-blind study. Drugs 52: pp. 26-9
- Dockhorn, RJ (1996) Ebastine relieves allergic rhinitis symptoms from l–24h post dose in a double-blind controlled field study [abstract]. Allergy 51: pp. 42
- Chamorro, M, Castellano, A, Vigaray, J (1998) Adverse reaction to antihistamines. Allergy 53: pp. 102
- Bernstein, DI, Lim, JC, Georges, GC (1999) The comparative efficacy and safety of ebastine 20 mg and 10 mg once daily (OD) and loratidine 10 mg OD vs placebo during 4 week treatment of seasonal allergic rhinitis (SAR). J Allergy Clin Immunol 103: pp. S526-7
- Connell, L, Alderfer, V, Garcia, J (1995) Electrocardiographic evaluation of ebastine in double-blind allergic rhinitis clinical trials [abstract]. Allergy 50: pp. 105
- Aoki, Y, Funabashi, H, Terada, Y (1994) Reproductive and developmental toxicity studies of ebastine (2): teratogenicity study in rats [in Japanese]. Yakuri to Chiryo 22: pp. 1193-215
- Jáuregui, J, Roberts, DJ (1992) Preclinical safety studies with ebastine. IV. Acute, chronic and reproductive toxicity, mutagenicity and carcinogenicity. Drugs Today 28: pp. 45-56
- Parfitt, K (1999) Martindale: the complete drug reference. Pharmaceutical Press, London
- Paserchia, LA, Hewett, J, Woosley, RL (1994) Effects of ketoconazole on QTc [abstract no. PI-92]. Clin Pharmacol Ther 55: pp. 146
- Ebastel: ebastina 10mg. Contraindicaciones [online]. Available from: URL: http://www.encolombia.com [Accessed 2000 Feb 10]
- Horak, F, Stübner, UP (1998) New trends in allergic rhinitis. Allergy Clin Immunol Int 10: pp. 81-7
- Kozma, CM, Sadik, MK, Watrous, ML (1996) Economic outcomes for the treatment of allergic rhinitis. PharmacoEconomics 10: pp. 4-13
- Mackay, IS, Durham, SR (1998) Perennial rhinitis. BMJ 316: pp. 917-20
- Parikh, A, Scadding, GK (1997) Seasonal allergic rhinitis. BMJ 314: pp. 1392-5
- Nightingale, CH (1996) Treating allergic rhinitis with second-generation antihistamines. Pharmacotherapy 16: pp. 905-14
- Lund, VJ (1996) Seasonal allergic rhinitis — a review of current therapy. Allergy 51: pp. 5-7
- Milne, T (1994) International consensus report on diagnosing and managing rhinitis. Inpharma 946: pp. 13-4
- Dykewicz, MS, Fineman, S (1998) Executive summary of joint task force practice parameters on diagnosis and management of rhinitis. Ann Allergy Asthma Immunol 2: pp. 463-8
- Drug Ther Perspect 122: pp. 5-8
- Bousquet, J, Demoly, P (1996) Specific immunotherapy for allergic rhinitis in children. Allergy Clin Immunol Int 8: pp. 145-50
- Guarderas, JC (1996) Rhinitis and sinusitis: office management. Mayo Clin Proc 71: pp. 882-8
- Physicians’ Desk Reference. 54th ed. Montvale: Medical Economics Company, 2000
- Handley, DA, Magnetti, A, Higgins, AJ (1998) Therapeutic advantages of third generation antihistamines. Expert Opin Invest Drug 7: pp. 1045-54
- Markham, A, Wagstaff, AJ (1998) Fexofenadine. Drugs 55: pp. 269-74
- Pinto, YM, Gelder, IC, Heeringa, M (1999) QT lengthening and life-threatening arrhythmias associated with fexofenadine [letter]. Lancet 353: pp. 980
Volume 59, Issue 4 , pp 981-1006
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors